LivaNova PLC (NASDAQ:LIVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have received an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $79.3750.

Several analysts have issued reports on the company. Mizuho lifted their price target on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Thursday, May 7th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Robert W. Baird lowered their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating and issued a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Finally, Stifel Nicolaus set a $80.00 target price on LivaNova in a research report on Wednesday, February 25th.

Insider Activity

In related news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Segall Bryant & Hamill LLC acquired a new stake in shares of LivaNova in the first quarter valued at about $665,000. Janus Henderson Group PLC increased its position in shares of LivaNova by 1,978.8% in the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock valued at $29,961,000 after acquiring an additional 448,703 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of LivaNova by 103.6% in the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after acquiring an additional 826 shares during the last quarter. California State Teachers Retirement System increased its position in shares of LivaNova by 24.3% in the first quarter. California State Teachers Retirement System now owns 63,665 shares of the company’s stock valued at $4,047,000 after acquiring an additional 12,447 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new stake in shares of LivaNova in the first quarter valued at about $956,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

LIVN opened at $79.39 on Friday. The business’s 50-day moving average price is $69.08 and its two-hundred day moving average price is $65.77. LivaNova has a 1 year low of $41.01 and a 1 year high of $80.74. The company has a market capitalization of $4.36 billion, a price-to-earnings ratio of 40.71 and a beta of 0.88. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The firm had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. During the same quarter last year, the business posted $0.88 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Equities analysts expect that LivaNova will post 3.72 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.